These scans included patients with a wide variety of cancers: lung cancer, melanoma, lymphoma, head and neck cancer, breast cancer, and prostate-specific membrane antigen (PSMA) PET/CT scans of patients with prostate cancer. This evidence concerns the gene FOLH1 and melanoma.